Study reveals why immunotherapy works differently in liver, lung, and brain tumors
NCT ID NCT07631611
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites respond better than others, which could help personalize cancer treatment in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- immune checkpoint inhibitors (ICB therapy)
- What this could lead to
- If successful, this could help doctors choose better immunotherapy strategies based on where a patient's cancer has spread.
- What could go wrong
- This is a retrospective study that looks back at medical records, so it cannot prove cause and effect. Results may not apply to all patients or treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can an immune booster after lung cancer surgery keep the disease at bay?
- Can engineered immune cells target a common ovarian cancer protein?
- Can we predict frailty in serious illness? a large study investigates
- Can a new imaging tracer outperform standard scans in finding hidden tumors?